Acalnib 100 mg contains Acalabrutinib, a highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor, used primarily in the treatment of certain B-cell blood cancers. It offers a targeted approach to managing cancers like chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL).

Designed for oral administration, Acalnib represents a new generation of BTK inhibitors, offering greater selectivity and fewer off-target effects, improving tolerability for long-term use.

Mechanism of Action

Acalabrutinib works by irreversibly binding to BTK, an enzyme that plays a crucial role in the B-cell receptor signaling pathway. This pathway is essential for the growth and survival of malignant B-cells.

How it works:

• Inhibits BTK activity

• Disrupts cancer cell signaling

• Induces cancer cell death and halts proliferation

• Minimizes impact on other immune cells (due to selectivity)

  Uses / Indications

  Acalnib (Acalabrutinib) is indicated for the treatment of:

  Approved Indications:

  • Chronic Lymphocytic Leukemia (CLL)

  • Small Lymphocytic Lymphoma (SLL)

  • Mantle Cell Lymphoma (MCL) – in adults who have received at least one prior therapy

  It is often used as:

  • Monotherapy, or

  • In combination with other agents (e.g., obinutuzumab)

    Adverse Effects

    While Acalabrutinib is generally well tolerated, certain side effects may occur due to its impact on blood and immune cells.

    Common Side Effects:

    • Headache (one of the most reported)

    • Diarrhea

    • Fatigue

    • Cough

    • Muscle aches (myalgia)

    • Upper respiratory tract infections

    Serious Side Effects (less common):

    • Bleeding complications, including bruising or nosebleeds

    • Atrial fibrillation or other heart rhythm abnormalities

    • Low blood cell counts (anemia, thrombocytopenia, neutropenia)

    • Infections, particularly in patients with weakened immunity